| 5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase |
<enzyme> Catalyses conversion of 5 alpha-dihydroprogesterone to 3 alpha -hydroxy-5 alpha-pregnane-20-one
Registry number: EC 1.1.1.-
Synonym: 5-dp-3 alpha-hso, NADPH-5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase, alpha-hsor
(26 Jun 1999) |
| 5 beta-cholestane-3 alpha,7 alpha-diol 26-hydroxylase |
<enzyme> Nadp-dependent
Registry number: EC 1.14.13.-
(26 Jun 1999) |
| 7 alpha-hydroxy-4-cholesten-3-one-12 alpha monooxygenase |
<enzyme> Liver microsomal enzyme active in conversion of cholesterol to cholic acid; introduces a 12 alpha-hydroxyl group into the steroid nucleus of cholesterol
Registry number: EC 1.14.99.-
Synonym: 7-hco-monooxygenase, hco 12 alpha-hydroxylase
(26 Jun 1999) |
| acetyl-CoA:alpha-glucosaminide acetyltransferase |
<enzyme> An enzyme involved in the synthesis of certain carbohydrate moieties on proteins. A deficiency of this enzyme leads to mucopolysaccharidosis type III C.
(05 Mar 2000) |
| adrenergic alpha-agonists |
Drugs that selectively bind to and activate alpha adrenergic receptors.
(12 Dec 1998) |
| adrenergic alpha-antagonists |
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(12 Dec 1998) |
| alpha |
First letter of the Greek alphabet, a.
(05 Mar 2000) |
| alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase |
<enzyme> Incorporates n-acetyglucosamine as the third branch of complex n-glycosyl-oligosaccharide of hen oviduct
Registry number: EC 2.4.1.145
Synonym: glcnac-transferase iv, n-acetylglucosaminyltransferase iv, udp-glcnac-gngn(glcnac to man alpha1-3)beta 4-n-acetylglucosaminyltransferase iv
(26 Jun 1999) |
| alpha-1,4-glucan lyase |
<enzyme> Degrades alpha-1,4-glucan to produce 1,5-anhydrofructose; from seaweeds gracilariopsis lemaneiformis and gracilaria verrucosa; mw 111 kD; amino acid sequence has been determined
Registry number: EC 4.2.2.-
Synonym: alpha-1,4-glucan 4-lyase
(26 Jun 1999) |
| alpha 1-4-mannosyltransferase |
<enzyme> From mycobacterium smegmatis; involved in methylmannose polysaccharide elongation; GDP-mannose is donor
Registry number: EC 2.4.1.-
(26 Jun 1999) |
| alpha(1-6)mannosidase |
<enzyme> Human lysosomal enzyme highly specific for alpha 1-6 mannose residues; inhibited by swainsonine; not the same enzyme which is deficient in alpha-mannosidosis
Registry number: EC 3.2.1.-
(26 Jun 1999) |
| alpha 1,6-mannosyltransferase |
<enzyme> From saccharomyces cerevisiae; adds mannose residues in an alpha-1,6-linkage to man8glcnac and man9glcnac in the biosynthesis of the outer chain of yeast mannoproteins
Registry number: EC 2.4.1.-
(26 Jun 1999) |
| alpha-1 antichymotrypsin |
<chemical> Glycoprotein found in alpha(1)-globulin region in human serum. It is an inhibiter of the digestive protease, chymotrypsin and other chymotrypsin-like proteinases in vivo and has cytotoxic killer-cell activity in vitro.
The protein also has a role as an acute-phase protein and is active in the control of immunologic and inflammatory processes, and as a tumour marker. It is a member of the serpin superfamily.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998) |
| alpha-1 antitrypsin |
<chemical> Plasma glycoprotein member of the serpin superfamily which inhibits trypsin, neutrophil elastase, and other proteolytic enzymes. Commonly referred to as alpha 1-proteinase inhibitor (a1pi), it exists in over 30 different biochemical variant forms known collectively as the pi (protease inhibitor) system.
Hereditary deficiency is associated with pulmonary emphysema.
See: alpha-1 antitrypsin deficiency
Pharmacological action: serine proteinase inhibitors, trypsin inhibitors.
(12 Dec 1998) |
| alpha-1 antitrypsin deficiency |
<chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues.
The lack of this protein leads to damage of various organs, but mainly to the lung and liver.
symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
(12 Dec 1998) |
